Alfasigma, an Italy based, privately owned, medium-sized pharmaceutical company, has entered into a share purchase agreement with Sever Life Sciences for the sale of 100% of the shares of Nordic Group BV and its subsidiaries, a specialty pharmaceutical company with direct operations in Europe, Canada and Japan.
Financial terms are not disclosed.
The acquisition will add Nordic Pharma’s established rheumatoid arthritis business, led by the Nordimet methotrexate franchise, to Alfasigma’s rheumatology portfolio, which includes the Jyseleca franchise. It will also deepen Alfasigma’s commercial reach through direct operations in 18 countries across Europe and add commercial platforms in Canada and Japan. In addition to rheumatology, the acquisition includes Nordic Pharma’s portfolio in women’s health, critical care and ophthalmology. Nordic Pharma employees 265 and reported 2025 revenue of approximately €190m.
“Alfasigma is the right partner for Nordic Pharma as we enter our next phase of growth,” said Charlotte Phelps, CEO, Nordic Group. “We look forward to combining our experience to support patients.”
The transaction supports Alfasigma’s M&A-led growth strategy as it actively expands its international specialty and rare business, with a focus on gastroenterology and immunology.
“Alfasigma is pursuing a deliberate strategy to identify the right opportunities to build our global specialty and rare disease business, focused on areas of significant unmet need in gastroenterology and immunology,” said Francesco Balestrieri, CEO, Alfasigma. “The acquisition of Nordic Pharma marks a decisive step forward in that journey, strengthening our European presence and expanding our rheumatology portfolio. By combining our portfolios, scientific expertise and talented teams, we are better positioned to deliver meaningful innovation and value for patients and shareholders.”
Alfasigma’s products are distributed in more than 100 markets worldwide. The company employs approximately 4,000 people. Its portfolio ranges from consumer healthcare products and primary care treatments to specialty and rare disease medications, with key therapeutic focus on gastroenterology, immunology, and vascular health.
Holding company, Sever will continue to focus on the development of its remaining businesses: Sever Pharma Solutions, Farmaprim, Esperante Development and Nordic Pharma Inc.
